NYSEARCA:IDNA iShares Genomics Immunology and Healthcare ETF (IDNA) Price, Holdings, & News $20.64 +0.13 (+0.63%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsOwnershipRatingsShort InterestBuy This Stock About iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IDNA alerts:Sign Up Key Stats Today's Range$20.40▼$21.0050-Day Range$19.13▼$21.5052-Week Range$17.26▼$25.80Volume19,526 shsAverage Volume31,231 shsMarket Capitalization$106.30 millionAssets Under Management$105.83 millionDividend Yield1.26%Net Expense Ratio0.47%Aggregate RatingModerate Buy ETF Overview The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock. Read More iShares Genomics Immunology and Healthcare ETF ExpensesTypeIDNATheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.47%0.57%0.56%0.51%0.53%Other Expenses0.00%0.58%0.56%0.59%0.56%Total Expense0.47%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.76%-0.66%-0.71%-0.63%Net Expense0.47%0.60%0.63%0.58%0.60% Receive IDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Genomics Immunology and Healthcare ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address IDNA ETF News HeadlinesiShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Shares Down 0.2% - Time to Sell?June 24, 2025 | americanbankingnews.comIDNA: The Cutting Edge Of Medical Science Is A Risky InvestmentApril 20, 2025 | seekingalpha.com3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 1 at 2:00 AM | Timothy Sykes (Ad)Ishares Healthcare Innov Ucits Etf Acc Share Price (HEAL.MI)November 7, 2024 | lse.co.ukiShares S&P 500 Health Care Sector UCITS ETF USD (Acc) (IUHC.L)September 25, 2024 | finance.yahoo.comiDNA Genomics Public LtdMay 18, 2024 | morningstar.comMSee More Headlines IDNA ETF - Frequently Asked Questions How have IDNA shares performed this year? iShares Genomics Immunology and Healthcare ETF's stock was trading at $22.63 at the beginning of 2025. Since then, IDNA shares have decreased by 8.8% and is now trading at $20.64. View the best growth stocks for 2025 here. How do I buy shares of iShares Genomics Immunology and Healthcare ETF? Shares of IDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Genomics Immunology and Healthcare ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Genomics Immunology and Healthcare ETF investors own include iShares Micro-Cap ETF (IWC), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssueriShares Fund NameiShares Genomics Immunology and Healthcare ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IDNA Inception Date6/11/2019 Fund ManagerJennifer Hsui, Greg Savage, Paul Whitehead WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE FactSet Global Genomics and Immuno Biopharma Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings61 Fund Statistics Assets Under Management$105.83 million Average Daily Volume$0.00 Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorState Street Bank and Trust Company AdvisorBlackRock Fund Advisors CustodianState Street Bank and Trust Company DistributorBlackRock Investments, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume1 Put Options2 Call Options1 Short Interest4,600 shs Miscellaneous Outstanding Shares5,150,000Beta0.90 Creation Unit50,000 Creation Fee$850.00 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report Top 10 IDNA HoldingsBeOne Medicines Ltd.Holding Weight: 6.00%GSK plcHolding Weight: 5.68%Exelixis (NASDAQ:EXEL)Holding Weight: 5.46%Roche Holding AGHolding Weight: 5.30%AstraZeneca PLCHolding Weight: 5.13%Genmab A/SHolding Weight: 4.91%Takeda Pharmaceutical Company LimitedHolding Weight: 4.87%SpringWorks Therapeutics (NASDAQ:SWTX)Holding Weight: 4.83%SanofiHolding Weight: 4.82%Incyte (NASDAQ:INCY)Holding Weight: 4.28%Full Holdings DetailsIDNA Sector ExposureIDNA Industry Exposure This page (NYSEARCA:IDNA) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Genomics Immunology and Healthcare ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Genomics Immunology and Healthcare ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.